Patents by Inventor Leila Sevigny

Leila Sevigny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering
    Patent number: 12195555
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
    Type: Grant
    Filed: September 19, 2023
    Date of Patent: January 14, 2025
    Inventors: Nicolas Gourdin, Laurent Gauthier, Alexandre Tang, Marielle Chiron, Angela Virone-Oddos, Alessandro Masiero, Jochen Beninga, Ingo Focken, Sambasiva Rao, Yanfeng Zhou, Leila Sevigny
  • Anti-NGF antibodies and uses thereof
    Patent number: 12110322
    Abstract: The invention provides novel anti-NGF proteins, antibodies, and NGF-binding fragments thereof which inhibit association of NGF with TrkA and/or p75 and are suitable for administration to a canine or feline subject. The invention also provides novel compositions and methods of treating pain or eliciting an analgesic effect in a canine or feline subject, comprising administering an effective amount of an anti-NGF protein, antibody or fragment thereof. The methods and compositions are used to treat or prevent NGF-related disorders.
    Type: Grant
    Filed: July 6, 2023
    Date of Patent: October 8, 2024
    Assignee: INVETX, INC.
    Inventors: William Brondyk, Jordan Willis, Leila Sevigny
  • Multispecific binding molecules having specificity to dystroglycan and laminin-2
    Patent number: 11254737
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 22, 2022
    Assignee: SANOFI
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Multispecific binding molecules having specificity to dystroglycan and laminin-2
    Patent number: 10626169
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: April 21, 2020
    Assignee: Sanofi
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Multispecific binding molecules having specificity to dystroglycan and laminin-2
    Publication number: 20180237511
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Application
    Filed: February 16, 2018
    Publication date: August 23, 2018
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu